Revenue
2019
2020
2021
2022
2023
2024
2025
2026
ELITE PHARMACEUTICALS INC /NV/ (ELTP)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $148.9M | $84.0M | $56.6M | $34.2M | $32.3M | $25.4M | $18.0M | $7.6M | $7.5M | $9.6M | $12.5M | $5.0M | $4.6M | $3.4M | $2.4M | $4.3M |
| Gross profit | $75.0M | $40.1M | $26.4M | $16.6M | $14.8M | $11.9M | $8.0M | $2.9M | $3.9M | $3.7M | $8.0M | $2.0M | $1.4M | $1.1M | $1.4M | $1.6M |
| Research & development | $5.7M | $8.0M | $6.9M | $6.2M | $4.1M | $5.1M | $5.5M | $7.6M | $9.6M | $8.3M | $12.4M | $14.7M | $4.0M | $975,250 | $1.7M | $1.4M |
| Operating expenses | $25.9M | $20.5M | $15.6M | $12.9M | $9.7M | $9.8M | $10.3M | $12.0M | $13.0M | $11.1M | $16.3M | $18.5M | $6.6M | $2.7M | $3.4M | $2.5M |
| Operating income | $49.1M | $19.6M | $10.8M | $3.7M | $5.1M | $2.1M | −$2.3M | −$9.2M | −$9.1M | −$7.4M | −$8.3M | −$16.5M | −$5.3M | −$1.6M | −$2.0M | −$885,760 |
| EBITDAderived | $50.2M | $20.8M | $12.1M | $5.0M | $6.3M | $3.4M | −$965,613 | −$7.9M | −$8.1M | −$6.6M | −$7.7M | −$15.9M | −$4.8M | −$1.1M | −$1.5M | −$402,287 |
| Net income | $44.9M | −$4.3M | $20.1M | $3.6M | $8.9M | $5.1M | −$2.2M | −$9.3M | −$3.7M | $3.8M | −$683,012 | $5.2M | −$41.3M | $1.5M | −$15.1M | −$13.6M |
| Basic EPSper diluted share | $0.04 | $0.00 | $0.02 | $0.00 | $0.01 | $0.01 | $0.00 | -$0.01 | $0.00 | $0.03 | -$0.01 | $0.05 | -$0.21 | $0.00 | -$0.06 | -$0.14 |
| Diluted EPSper diluted share | $0.03 | $0.00 | $0.02 | $0.00 | $0.01 | $0.00 | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.21 | $0.00 | -$0.06 | -$0.14 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 2, 2025Form 4 | Plassche DouglasEVP Operations | Sellcommon stock | 800.0K | $0.62 | $496.0K | 3.50M |
| Aug 22, 2025Form 4 | ELITE PHARMACEUTICALS INC /NV/EVP Operations | SellCommon Stock | 500.0K | $0.52 | $260.0K | 1.80M |
| Jul 10, 2025Form 4 | Kirkov KirkoChief Commercial Officer | BuyCommon Stock | 16.4K | $0.59 | $9.7K | 16.4K |
| Jul 8, 2025Form 4 | Plassche DouglasEVP Operations | SellStock Options (right to buy) | 200.0K | $0.58 | $116.0K | 2.30M |
| Oct 24, 2024Form 4 | Plassche DouglasSVP of Operations | SellCommon Stock | 333.9K | $0.51 | $170.3K | 0 |